100 plus Papers from the Editorial Board

Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Jun 10;6(16):14318-28.

PMID: 26015409

Mitochondrial compartmentalized protein folding and tumor cell survival.

Altieri DC.

Oncotarget. 2011 Apr;2(4):347-51. Review.

PMID: 21555789

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ.

Oncotarget. 2015 May 10;6(13):10746-58.

PMID: 25883215

Dopamine signaling: target in glioblastoma.

Bartek J, Hodny Z.

Oncotarget. 2014 Mar 15;5(5):1116-7. No abstract available.

PMID: 24657925

Cytokine-induced 'bystander' senescence in DDR and immuno-surveillance.

Hodny Z, Hubackova S, Bartek J.

Oncotarget. 2013 Oct;4(10):1552-3. No abstract available.

PMID: 24145286

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.

Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P, Christensen C.

Oncotarget. 2013 Apr;4(4):584-99.

Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.

Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM.

Oncotarget. 2015 Jan 1;6(1):56-70.

PMID: 25474141

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N.

Oncotarget. 2014 Feb 15;5(3):587-98.

PMID: 24583822

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB.

Oncotarget. 2013 Nov;4(11):2067-79.

PMID: 24162015

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ.

Oncotarget. 2013 Oct;4(10):1737-47.

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.

Bansal N, Mishra PJ, Stein M, DiPaola RS, Bertino JR.

Oncotarget. 2015 Jun 20;6(17):15321-31.

PMID: 26036314

Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma.

Capaccione KM, Hong X, Morgan KM, Liu W, Bishop JM, Liu L, Markert E, Deen M, Minerowicz C, Bertino JR, Allen T, Pine SR.

Oncotarget. 2014 Jun 15;5(11):3636-50.

PMID: 25004243

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Oncotarget. 2014 Feb 28;5(4):901-7.

An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival.

Snijders AM, Langley S, Mao JH, Bhatnagar S, Bjornstad KA, Rosen CJ, Lo A, Huang Y, Blakely EA, Karpen GH, Bissell MJ, Wyrobek AJ.

Oncotarget. 2014 Jun 30;5(12):4011-25.

PMID: 24994117

NFkB disrupts tissue polarity in 3D by preventing integration of microenvironmental signals.

Becker-Weimann S, Xiong G, Furuta S, Han J, Kuhn I, Akavia UD, Pe'er D, Bissell MJ, Xu R.

Oncotarget. 2013 Nov;4(11):2010-20.

PMID: 24243820

Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to ?-irradiation.

Yan Y, Hein AL, Etekpo A, Burchett KM, Lin C, Enke CA, Batra SK, Cowan KH, Ouellette MM.

Oncotarget. 2014 Nov 15;5(21):10251-70.

PMID: 25344910

A differentially expressed set of micrornas in cerebro-spinal fluid (CSF) can diagnose CNS malignancies.

Drusco A, Bottoni A, Lagana' A, Acunzo M, Fassan M, Cascione L, Antenucci A, Kumchala P, Vicentini C, Gardinam MP, Alder H, Carosi MA, Ammirati M, Gherardi S, Luscri' M, Carapella C, Zanesi N, Croce CM.

Oncotarget. 2015 May 28. [Epub ahead of print]

PMID: 26246487

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, Narducci MG, Caprini E, Pekarsky Y, Croce CM, Sabbioni S, Russo G, Negrini M.

Oncotarget. 2015 Jun 10. [Epub ahead of print]

PMID: 26090867

MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression.

Kim T, Cui R, Jeon YJ, Fadda P, Alder H, Croce CM.

Oncotarget. 2015 May 11. [Epub ahead of print]

PMID: 26003165

RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.

Lee TJ, Haque F, Shu D, Yoo JY, Li H, Yokel RA, Horbinski C, Kim TH, Kim SH, Kwon CH, Nakano I, Kaur B, Guo P, Croce CM.

Oncotarget. 2015 Jun 20;6(17):14766-76.

PMID: 25885522

miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells.

Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM, Aqeilan RI.

Oncotarget. 2015 Mar 10;6(7):4920-35.

PMID: 25749032

Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis.

Fassan M, Dall'Olmo L, Galasso M, Braconi C, Pizzi M, Realdon S, Volinia S, Valeri N, Gasparini P, Baffa R, Souza RF, Vicentini C, D'Angelo E, Bornschein J, Nuovo GJ, Zaninotto G, Croce CM, Rugge M.

Oncotarget. 2014 Aug 30;5(16):7162-71.

PMID: 25216530

Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner.

Armenia J, Fabris L, Lovat F, Berton S, Segatto I, D'Andrea S, Ivan C, Cascione L, Calin GA, Croce CM, Colombatti A, Vecchione A, Belletti B, Baldassarre G.

Oncotarget. 2014 Mar 15;5(5):1185-97.

PMID: 24727437

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.

Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K.

Oncotarget. 2014 Mar 15;5(5):1174-84.

PMID: 24632568

LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.

Lovat F, Ishii H, Schiappacassi M, Fassan M, Barbareschi M, Galligioni E, Gasparini P, Baldassarre G, Croce CM, Vecchione A.

Oncotarget. 2014 Feb 28;5(4):970-7.

PMID: 24448468

MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia.

Visone R, Veronese A, Balatti V, Croce CM.

Oncotarget. 2012 Feb;3(2):195-202.

PMID: 22350310

Is miR-29 an oncogene or tumor suppressor in CLL?

Pekarsky Y, Croce CM.

Oncotarget. 2010 Jul;1(3):224-7.

PMID: 20936047

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.

Oncotarget. 2015 May 20. [Epub ahead of print]

PMID: 26254279

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.

Oncotarget. 2014 Feb 28;5(4):908-15.

PMID: 24659719

Kinase inhibitor therapy in CML: it's what's inside that counts.

Eide CA, Druker BJ, O'Hare T.

Oncotarget. 2013 Sep;4(9):1332-3. No abstract available.

PMID: 23934763

Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein.

McKee CM, Ding Y, Zhou J, Li C, Huang L, Xin X, He J, Allen JE, El-Deiry WS, Cao Y, Muschel RJ, Xu D.

Oncotarget. 2015 Feb 28;6(6):3784-96.

PMID: 25686839

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity.

Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS.

Oncotarget. 2014 Dec 30;5(24):12728-37.

PMID: 25587031

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs.

Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL, Joudeh J, Zhu J, El-Deiry WS.

Oncotarget. 2014 Apr 15;5(7):1753-60.

PMID: 24334302

Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on ?-catenin.

Allen JE, El-Deiry WS.

Oncotarget. 2013 Feb;4(2):184-91.

PMID: 23468473

Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.

Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS.

Oncotarget. 2011 Oct;2(10):752-60.

PMID: 21987585

Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression.

Benavente CA, Finkelstein D, Johnson DA, Marine JC, Ashery-Padan R, Dyer MA.

Oncotarget. 2014 Oct 30;5(20):9594-608.

PMID: 25338120

RB1 gene inactivation by chromothripsis in human retinoblastoma.

McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J, Mullighan C, Song G, Chen X, Wilson M, Brennan R, Pounds S, Becksfort J, Huether R, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Mardis ER, Wilson RK, Easton J, Zhang J, Downing JR, Ganguly A, Dyer MA.

Oncotarget. 2014 Jan 30;5(2):438-50.

PMID: 24509483

Cross-species genomic and epigenomic landscape of retinoblastoma.

Benavente CA, McEvoy JD, Finkelstein D, Wei L, Kang G, Wang YD, Neale G, Ragsdale S, Valentine V, Bahrami A, Temirov J, Pounds S, Zhang J, Dyer MA.

Oncotarget. 2013 Jun;4(6):844-59.

PMID: 23765217

The war on cancer: have we won the battle but lost the war?

Brennan R, Federico S, Dyer MA.

Oncotarget. 2010 Jun;1(2):77-83. No abstract available.

PMID: 20877440

p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.

Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, van Riggelen J, Plevritis S, Felsher DW.

Oncotarget. 2015 Feb 28;6(6):3563-77.

PMID: 25784651

Oncogene addiction: resetting the safety switch?

Li Y, Choi PS, Felsher DW.

Oncotarget. 2014 Sep 30;5(18):7986-7. No abstract available.

PMID: 25275297

"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.

DeChristopher BA, Fan AC, Felsher DW, Wender PA.

Oncotarget. 2012 Jan;3(1):58-66.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2015 Jun 24. [Epub ahead of print]

PMID: 26160841

RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.

Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A.

Oncotarget. 2015 Jul 20;6(20):17873-90. Review.

PMID: 26160835

Deregulation of dicer and mir-155 expression in liposarcoma.

Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G.

Oncotarget. 2015 Apr 30;6(12):10586-91.

PMID: 25888631

SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.

Casini N, Forte IM, Mastrogiovanni G, Pentimalli F, Angelucci A, Festuccia C, Tomei V, Ceccherini E, Di Marzo D, Schenone S, Botta M, Giordano A, Indovina P.

Oncotarget. 2015 May 20;6(14):12421-35.

PMID: 25762618

Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrence.

Finicelli M, Benedetti G, Squillaro T, Pistilli B, Marcellusi A, Mariani P, Santinelli A, Latini L, Galderisi U, Giordano A.

Oncotarget. 2014 Oct 30;5(20):9678-88.

PMID: 25127259

FAS/FASL are dysregulated in chordoma and their loss-of-function impairs zebrafish notochord formation.

Ferrari L, Pistocchi A, Libera L, Boari N, Mortini P, Bellipanni G, Giordano A, Cotelli F, Riva P.

Oncotarget. 2014 Jul 30;5(14):5712-24.

PMID: 25071022

p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.

Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, Barba M.

Oncotarget. 2014 Nov 15;5(21):10382-92.

PMID: 25071015

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D, Gullà A, Neri A, Taverna S, D'Aquila P, Alessandro R, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2014 May 30;5(10):3039-54.

PMID: 24839982

pRb controls estrogen receptor alpha protein stability and activity.

Caligiuri I, Toffoli G, Giordano A, Rizzolio F.

Oncotarget. 2013 Jun;4(6):875-83.

PMID: 23900261

In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.

Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2013 Feb;4(2):242-55.

PMID: 23479461

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.

Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2012 Oct;3(10):1246-58.

PMID: 23100393

Properties of mechano-transduction via simulated microgravity and its effects on intracellular trafficking of VEGFR's.

Puca A, Russo G, Giordano A.

Oncotarget. 2012 Apr;3(4):426-34.

PMID: 22566481

A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma.

D'Agostino L, Giordano A.

Oncotarget. 2011 Dec;2(12):1055-74.

PMID: 22170762

NSP 5a3a: a potential novel cancer target in head and neck carcinoma.

D'agostino L, Giordano A.

Oncotarget. 2010 Oct;1(6):423-35.

PMID: 21311098

Functional consequence of the MET-T1010I polymorphism in breast cancer.

Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM.

Oncotarget. 2015 Feb 20;6(5):2604-14.

PMID: 25605252

Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives.

Liu B, Conroy JM, Morrison CD, Odunsi AO, Qin M, Wei L, Trump DL, Johnson CS, Liu S, Wang J.

Oncotarget. 2015 Mar 20;6(8):5477-89.

PMID: 25849937

Circulating miR-148b and miR-133a as biomarkers for breast cancer detection.

Shen J, Hu Q, Schrauder M, Yan L, Wang D, Medico L, Guo Y, Yao S, Zhu Q, Liu B, Qin M, Beckmann MW, Fasching PA, Strick R, Johnson CS, Ambrosone CB, Zhao H, Liu S.

Oncotarget. 2014 Jul 30;5(14):5284-94.

PMID: 25051376

Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.

Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ.

Oncotarget. 2014 Feb 15;5(3):824-40.

PMID: 24583788

Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges.

Liu B, Morrison CD, Johnson CS, Trump DL, Qin M, Conroy JC, Wang J, Liu S.

Oncotarget. 2013 Nov;4(11):1868-81. Review.

PMID: 24240121

Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue.

Luo W, Hu Q, Wang D, Deeb KK, Ma Y, Morrison CD, Liu S, Johnson CS, Trump DL.

Oncotarget. 2013 Sep;4(9):1472-83.

DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells.

Hossain MZ, Healey MA, Lee C, Poh W, Yerram SR, Patel K, Azad NS, Herman JG, Kern SE.

Oncotarget. 2013 Feb;4(2):298-309.

PMID: 23593653

A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.

Patel K, Yerram SR, Azad NA, Kern SE.

Oncotarget. 2012 Jul;3(7):678-85.

PMID: 22824673

FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer.

Scrimieri F, Calhoun ES, Patel K, Gupta R, Huso DL, Hruban RH, Kern SE.

Oncotarget. 2011 Jan-Feb;2(1-2):69-75.

PMID: 21378412

Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies.

Stoll G, Bindea G, Mlecnik B, Galon J, Zitvogel L, Kroemer G.

Oncotarget. 2015 May 20;6(14):11894-909.

PMID: 26059437

Quantification of cellular viability by automated microscopy and flow cytometry.

Sauvat A, Wang Y, Segura F, Spaggiari S, Müller K, Zhou H, Galluzzi L, Kepp O, Kroemer G.

Oncotarget. 2015 Apr 20;6(11):9467-75.

PMID: 25816366

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508.

PMID: 25537519

Immunogenic cell death inducers as anticancer agents.

Kepp O, Senovilla L, Kroemer G.

Oncotarget. 2014 Jul 30;5(14):5190-1. No abstract available.

PMID: 25114034

Immunosurveillance against cancer-associated hyperploidy.

Senovilla L, Galluzzi L, Marino G, Vitale I, Castedo M, Kroemer G.

Oncotarget. 2012 Nov;3(11):1270-1. No abstract available.

PMID: 23174699

Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.

Zhang F, Rothermund K, Gangadharan SB, Pommier Y, Prochownik EV, Lazo JS.

Oncotarget. 2012 Sep;3(9):998-1010.

PMID: 22948175

Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells.

Yi L, Sun Y, Levine A.

Oncotarget. 2014 Oct 15;5(19):8924-36.

PMID: 25238040

The maintenance of epigenetic states by p53: the guardian of the epigenome.

Levine AJ, Greenbaum B.

Oncotarget. 2012 Dec;3(12):1503-4. No abstract available.

PMID: 23237909

The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway.

Levine AJ, Harris CR, Puzio-Kuter AM.

Oncotarget. 2012 Nov;3(11):1301-7. No abstract available.

PMID: 23211569

Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.

Pickup MW, Hover LD, Guo Y, Gorska AE, Chytil A, Novitskiy SV, Moses HL, Owens P.

Oncotarget. 2015 Jun 10. [Epub ahead of print]

PMID: 26274893

Loss of Wave1 gene defines a subtype of lethal prostate cancer.

Sowalsky AG, Sager R, Schaefer RJ, Bratslavsky G, Pandolfi PP, Balk SP, Kotula L.

Oncotarget. 2015 May 20;6(14):12383-91.

PMID: 25906751

Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling.

Giorgi C, Bonora M, Missiroli S, Poletti F, Ramirez FG, Morciano G, Morganti C, Pandolfi PP, Mammano F, Pinton P.

Oncotarget. 2015 Jan 30;6(3):1435-45.

PMID: 25544762

Role of aberrant PI3K pathway activation in gallbladder tumorigenesis.

Lunardi A, Webster KA, Papa A, Padmani B, Clohessy JG, Bronson RT, Pandolfi PP.

Oncotarget. 2014 Feb 28;5(4):894-900.

PMID: 24658595

Shape-shifting and tumor suppression by PLZF.

Hobbs RM, Pandolfi PP.

Oncotarget. 2010 May;1(1):3-5. No abstract available.

PMID: 21293049

Exomic sequencing of four rare central nervous system tumor types.

Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N.

Oncotarget. 2013 Apr;4(4):572-83.

PMID: 23592488

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H.

Oncotarget. 2012 Jul;3(7):709-22.

PMID: 22869205

IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients.

He J, Wu J, Jiao Y, Wagner-Johnston N, Ambinder RF, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N.

Oncotarget. 2011 Mar;2(3):178-85.

PMID: 21399237

The pursuit of oncotargets through understanding defective cell regulation.

Qiao M, Shi Q, Pardee AB.

Oncotarget. 2010 Nov;1(7):544-51. Review.

PMID: 21317450

Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion.

Wang H, Sharma L, Lu J, Finch P, Fletcher S, Prochownik EV.

Oncotarget. 2015 Jun 30;6(18):15857-70.

PMID: 26036281

Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5.

Wang H, Chauhan J, Hu A, Pendleton K, Yap JL, Sabato PE, Jones JW, Perri M, Yu J, Cione E, Kane MA, Fletcher S, Prochownik EV.

Oncotarget. 2013 Jun;4(6):936-47.

PMID: 23801058

Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.

Zhang F, Rothermund K, Gangadharan SB, Pommier Y, Prochownik EV, Lazo JS.

Oncotarget. 2012 Sep;3(9):998-1010.

The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.

Correa RG, Krajewska M, Ware CF, Gerlic M, Reed JC.

Oncotarget. 2014 Mar 30;5(6):1666-82.

PMID: 24681825

New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.

Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG.

Oncotarget. 2015 Apr 30;6(12):9728-39.

PMID: 25797248

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.

Popovics P, Schally AV, Szalontay L, Block NL, Rick FG.

Oncotarget. 2014 Jun 30;5(12):4567-78.

PMID: 24994120

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.

Treszl A, Steiber Z, Schally AV, Block NL, Dezso B, Olah G, Rozsa B, Fodor K, Buglyo A, Gardi J, Berta A, Halmos G.

Oncotarget. 2013 Oct;4(10):1721-8.

PMID: 24077773

Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG.

Oncotarget. 2013 May;4(5):751-60.

PMID: 23744510

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG.

Oncotarget. 2013 Mar;4(3):422-32.

PMID: 23518876

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.

Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG.

Oncotarget. 2012 Sep;3(9):988-97.

PMID: 22941871

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].

Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M, Rick FG.

Oncotarget. 2012 Jul;3(7):686-99.

PMID: 22824624

HIF-1? and TAZ serve as reciprocal co-activators in human breast cancer cells.

Xiang L, Gilkes DM, Hu H, Luo W, Bullen JW, Liang H, Semenza GL.

Oncotarget. 2015 May 20;6(14):11768-78.

PMID: 26059435

Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype.

Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, Bullen JW, Samanta D, Liang H, Semenza GL.

Oncotarget. 2014 Dec 30;5(24):12509-27.

PMID: 25587023

Hypoxia-inducible factors enhance glutamate signaling in cancer cells.

Hu H, Takano N, Xiang L, Gilkes DM, Luo W, Semenza GL.

Oncotarget. 2014 Oct 15;5(19):8853-68.

PMID: 25326682

Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells.

Luo W, Semenza GL.

Oncotarget. 2011 Jul;2(7):551-6.

PMID: 21709315

Predicting response to HER2 kinase inhibition.

Settleman J.

Oncotarget. 2015 Jan 20;6(2):588-9.

PMID: 25655645

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.

Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan JP, Kirkpatrick DS, Settleman J.

Oncotarget. 2014 Sep 15;5(17):7328-41.

PMID: 25193862

A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation.

Nelson EA, Sharma SV, Settleman J, Frank DA.

Oncotarget. 2011 Jun;2(6):518-24. Review.

PMID: 21680956

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.

Corcoran RB, Settleman J, Engelman JA.

Oncotarget. 2011 Apr;2(4):336-46. Review.

PMID: 21505228

Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats.

Staedtke V, Bai RY, Sun W, Huang J, Kibler KK, Tyler BM, Gallia GL, Kinzler K, Vogelstein B, Zhou S, Riggins GJ.

Oncotarget. 2015 Mar 20;6(8):5536-46.

PMID: 25849940

Structural basis of nSH2 regulation and lipid binding in PI3K?.

Miller MS, Schmidt-Kittler O, Bolduc DM, Brower ET, Chaves-Moreira D, Allaire M, Kinzler KW, Jennings IG, Thompson PE, Cole PA, Amzel LM, Vogelstein B, Gabelli SB.

Oncotarget. 2014 Jul 30;5(14):5198-208.

PMID: 25105564

Exomic sequencing of four rare central nervous system tumor types.

Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N.

Oncotarget. 2013 Apr;4(4):572-83.

PMID: 23592488

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H.

Oncotarget. 2012 Jul;3(7):709-22.

PMID: 22869205

IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients.

He J, Wu J, Jiao Y, Wagner-Johnston N, Ambinder RF, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N.

Oncotarget. 2011 Mar;2(3):178-85.

PMID: 21399237

A robust approach to enhance tumor-selective accumulation of nanoparticles.

Qiao Y, Huang X, Nimmagadda S, Bai R, Staedtke V, Foss CA, Cheong I, Holdhoff M, Kato Y, Pomper MG, Riggins GJ, Kinzler KW, Diaz LA Jr, Vogelstein B, Zhou S.

Oncotarget. 2011 Jan-Feb;2(1-2):59-68.

PMID: 21378416

PI3K? inhibitors that inhibit metastasis.

Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, Zhou S.

Oncotarget. 2010 Sep;1(5):339-48.

PMID: 21179398

MYC regulates the non-coding transcriptome.

Hart JR, Roberts TC, Weinberg MS, Morris KV, Vogt PK.

Oncotarget. 2014 Dec 30;5(24):12543-54.

PMID: 25587025

In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.

Raffeiner P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, Vogt PK, Stefan E, Bister K.

Oncotarget. 2014 Oct 15;5(19):8869-78.

PMID: 25326649

Phosphorylation of AKT: a mutational analysis.

Hart JR, Vogt PK.

Oncotarget. 2011 Jun;2(6):467-76.

PMID: 21670491

Smooth muscle ?-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation.

Shi J, Sun M, Vogt PK.

Oncotarget. 2010 May;1(1):9-21.

PMID: 20634973

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.

Powers MV, Valenti M, Miranda S, Maloney A, Eccles SA, Thomas G, Clarke PA, Workman P.

Oncotarget. 2013 Nov;4(11):1963-75.

PMID: 24185264

The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design.

Couty S, Westwood IM, Kalusa A, Cano C, Travers J, Boxall K, Chow CL, Burns S, Schmitt J, Pickard L, Barillari C, McAndrew PC, Clarke PA, Linardopoulos S, Griffin RJ, Aherne GW, Raynaud FI, Workman P, Jones K, van Montfort RL.

Oncotarget. 2013 Oct;4(10):1647-61.

PMID: 24072592

Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.

Saturno G, Valenti M, De Haven Brandon A, Thomas GV, Eccles S, Clarke PA, Workman P.

Oncotarget. 2013 Aug;4(8):1185-98.

PMID: 23852390

Inhibiting the molecular evolution of cancer through HSP90.

Martins AS, Davies FE, Workman P.

Oncotarget. 2012 Oct;3(10):1054-6. No abstract available.

PMID: 23175477

Shock about heat shock in cancer.

de Billy E, Travers J, Workman P.

Oncotarget. 2012 Aug;3(8):741-3.

PMID: 22964629

A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability.

Workman P, Davies FE.

Oncotarget. 2011 Apr;2(4):277-80. No abstract available.

PMID: 21515932

Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.

Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, Workman P, Leach MO.

Oncotarget. 2010 Jul;1(3):185-97.

PMID: 21037799

Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC